Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 47 points (-0.3%) at 15,521 as of Wednesday, July 24, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 716 issues advancing vs. 2,228 declining with 95 unchanged. The Drugs industry currently sits down 0.6% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Regeneron Pharmaceuticals ( REGN), down 1.0%, and Teva Pharmaceutical Industries ( TEVA), down 0.5%. TheStreet would like to highlight 4 stocks pushing the industry lower today: 4. Sarepta Therapeutics ( SRPT) is one of the companies pushing the Drugs industry lower today. As of noon trading, Sarepta Therapeutics is down $6.79 (-14.6%) to $39.64 on heavy volume. Thus far, 10.4 million shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $38.39-$46.36 after having opened the day at $45.00 as compared to the previous trading day's close of $46.43. Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Sarepta Therapeutics has a market cap of $1.5 billion and is part of the health care sector. Shares are up 79.7% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Sarepta Therapeutics Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.